FIELD: medicine.
SUBSTANCE: present group of inventions refers to medicine, namely to therapy and endocrinology, and concerns using a protein kinase C (PKC) inhibitor for preventing or treating post-transplantation insulin-producing cell rejection. That is ensured by an effective amount of 3-(1.H.-indol-3-yl)-4-[2-(4-methylpiperazin-1-yl)quinazolin-4-yl]pyrrol-2,5-dione or a pharmaceutically acceptable salt thereof.
EFFECT: preventing or treating the post-transplantation insulin-producing cell rejection.
4 cl
Authors
Dates
2013-10-10—Published
2007-12-05—Filed